Related Experiment Video
Updated: Jun 22, 2026
11:13
Composite Scaffolds of Interfacial Polyelectrolyte Fibers for Temporally Controlled Release of Biomolecules
Published on: August 19, 2015
8.5K
Dual release kinetics in a single dosage from core-shell hydrogel scaffolds
Finaz Khan1, Debbethi Bera2, Santanu Palchaudhuri3
1Amity Institute of Applied Sciences, Department of Chemistry, Amity University Kolkata Major Arterial Road, Action Area II, Kadampukur Village, Rajarhat Newtown West Bengal 700135 India sdas@kol.amity.edu ssmtdas@gmail.com.
RSC Advances
|May 13, 2022
Summary
Novel core-shell drug delivery systems were developed using sodium deoxycholate and trishydroxymethylaminomethane (NaDC-Tris) to achieve dual, variable release rates for two drugs. These systems show minimal toxicity and potential for combination therapy.
Area of Science:
- Materials Science
- Biomedical Engineering
- Drug Delivery Systems
Background:
- Microencapsulation enables sustained and controlled drug delivery.
- Dual release kinetics enhance the applicability of drug delivery devices.
- Novel core-shell scaffolds offer potential for delivering multiple therapeutics.
Purpose of the Study:
- To develop novel core-shell scaffolds (NaDC-Tris) for delivering two drugs with distinct release rates.
- To investigate the microstructural properties and release kinetics of these core-shell systems.
- To assess the biocompatibility of the developed drug delivery vehicles.
Main Methods:
- Synthesis and characterization of NaDC-Tris core-shell scaffolds.
- X-ray diffraction (XRD), sol-gel transition temperature, rheology, and fluorescence studies.
- In vitro release studies using model drugs Fluorescein (FL) and Rhodamine B (RhB).
- Cell viability assays on NMuMG and WI-38 cells.
Main Results:
- Core-shell systems showed altered microstructural properties compared to pure hydrogels.
- Distinct release kinetics were observed for drugs in the core and shell.
- The 25@250 system demonstrated rapid shell release (FL) and sustained core release (RhB).
- Cell viability studies indicated low toxicity of the NaDC-Tris scaffolds.
Conclusions:
- NaDC-Tris core-shell systems provide a platform for dual, variable drug release.
- These systems can be engineered for consecutive release of therapeutic agents.
- Potential applications include combination therapy for diseases like diabetes and cancer.
More Related Videos
Related Concept Videos
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.